{"id":380660,"date":"2020-11-13T07:03:26","date_gmt":"2020-11-13T12:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380660"},"modified":"2020-11-13T07:03:26","modified_gmt":"2020-11-13T12:03:26","slug":"tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","title":{"rendered":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference"},"content":{"rendered":"<h2>\nFireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET\/ 7:20 PM GMT<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>NEW YORK, Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company\u2019s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference. The fireside chat is scheduled to take place on Tuesday, November 17, 2020, at 2:20 PM ET\/ 7:20 PM GMT.<\/p>\n<p>A live webcast of this presentation will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9jlVLKGB_r6paETmHcA758drwWlSH91p3z58XUeZhB_Nu99a3JUM1mkT97kDrYGG2f_nXbknn36mnfBmUjX-LRfiIk7EgYsGaRihvXAEInv6OIIaweXQcjN-JlsW6wao\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/ir.tgtherapeutics.com\/events<\/a>.<\/p>\n<p>\n        <strong>ABOUT TG THERAPEUTICS, INC.<\/strong><br \/>\n        <br \/>TG Therapeutics\u00a0is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as \u201cU2\u201d, targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.\u00a0Umbralisib (TGR-1202) is an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon.\u00a0Umbralisib is currently under review by the\u00a0U.S. Food and Drug Administration\u00a0(FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL)\u00a0who\u00a0have received at least one prior anti-CD20 based regimen or follicular lymphoma (FL)\u00a0who\u00a0have received at least two prior systemic therapies. The Company also has a fully enrolled Phase 3 clinical trial evaluating U2 in patients with treatment na\u00efve and relapsed\/refractory chronic lymphocytic leukemia (CLL), and two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis (RMS). Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton\u2019s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47\/CD19 bispecific antibody, TG-1801. TG Therapeutics\u00a0is headquartered in\u00a0New York City.<\/p>\n<p>CONTACT:<\/p>\n<p>Jenna Bosco<br \/>Senior Vice President, <br \/>Corporate Communications<br \/>TG Therapeutics, Inc.<br \/>Telephone: 212.554.4351<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=czhRCRnGYlzmNX20At2Cmz5qYgSvJUyZ5skCsG8EFuqi4dcn4RSC6B1d3lToEvKWrF_2mvaEdavY2caf_NalqQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@tgtxinc.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET\/ 7:20 PM GMT NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company\u2019s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference. The fireside chat is scheduled to take place on Tuesday, November 17, 2020, at 2:20 PM ET\/ 7:20 PM GMT. A live webcast of this presentation will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS, INC. TG Therapeutics\u00a0is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380660","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET\/ 7:20 PM GMT NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company\u2019s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference. The fireside chat is scheduled to take place on Tuesday, November 17, 2020, at 2:20 PM ET\/ 7:20 PM GMT. A live webcast of this presentation will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS, INC. TG Therapeutics\u00a0is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments &hellip; Continue reading &quot;TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\",\"datePublished\":\"2020-11-13T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"name\":\"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\",\"datePublished\":\"2020-11-13T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","og_description":"Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET\/ 7:20 PM GMT NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company\u2019s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference. The fireside chat is scheduled to take place on Tuesday, November 17, 2020, at 2:20 PM ET\/ 7:20 PM GMT. A live webcast of this presentation will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS, INC. TG Therapeutics\u00a0is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments &hellip; Continue reading \"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T12:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference","datePublished":"2020-11-13T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","name":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=","datePublished":"2020-11-13T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ5MSMzODI1NjY3IzIwMjA3OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380660"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}